```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:SSSPTA1600RXA

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  FEB 28   PATDPAFULL - New display fields provide for legal status
                   data from INPADOC
 NEWS  4  FEB 28   BABS - Current-awareness alerts (SDIs) available
 NEWS  5  MAR 02   GBFULL: New full-text patent database on STN
 NEWS  6  MAR 03   REGISTRY/ZREGISTRY - Sequence annotations enhanced
 NEWS  7  MAR 03   MEDLINE file segment of TOXCENTER reloaded
 NEWS  8  MAR 22   KOREAPAT now updated monthly; patent information enhanced
 NEWS  9  MAR 22   Original IDE display format returns to REGISTRY/ZREGISTRY
 NEWS  10 MAR 22   PATDPASPC - New patent database available
 NEWS  11 MAR 22   REGISTRY/ZREGISTRY enhanced with experimental property tags
 NEWS  12 APR 04   EPFULL enhanced with additional patent information and new
                   fields
 NEWS  13 APR 04   EMBASE - Database reloaded and enhanced
 NEWS  14 APR 18   New CAS Information Use Policies available online
 NEWS  15 APR 25   Patent searching, including current-awareness alerts (SDIs),
                   based on application date in CA/CAplus and USPATFULL/USPAT2
                   may be affected by a change in filing date for U.S.
                   applications.
 NEWS  16 APR 28   Improved searching of U.S. Patent Classifications for
                   U.S. patent records in CA/CAplus
 NEWS  17 MAY 23   GBFULL enhanced with patent drawing images
 NEWS  18 MAY 23   REGISTRY has been enhanced with source information from
                   CHEMCATS
 NEWS  19 JUN 06   The Analysis Edition of STN Express with Discover!
                   (Version 8.0 for Windows) now available
 NEWS  20 JUN 13   RUSSIAPAT: New full-text patent database on STN
 NEWS  21 JUN 13   FRFULL enhanced with patent drawing images
 NEWS  22 JUN 27   MARPAT displays enhanced with expanded G-group definitions
                   and text labels
 NEWS  23 JUL 01   MEDICONF removed from STN
 NEWS  24 JUL 07   STN Patent Forums to be held in July 2005
 NEWS  25 JUL 13   SCISEARCH reloaded
 NEWS  26 JUL 20   Powerful new interactive analysis and visualization software,
                   STN AnaVist, now available

 NEWS EXPRESS  JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.
```

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:29:57 ON 10 AUG 2005

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:30:12 ON 10 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 9 AUG 2005 HIGHEST RN 859282-03-4
DICTIONARY FILE UPDATES: 9 AUG 2005 HIGHEST RN 859282-03-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10826099.str



chain nodes :
12 13
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 14 15 16 17 18 19 20 21 22 23 24
chain bonds :
1-6 5-12 12-13 13-14 17-20
ring bonds :
1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11 14-15 14-19 15-16
16-17 17-18 18-19 20-21 20-24 21-22 22-23 23-24
exact/norm bonds :
1-2 1-5 1-6 2-3 3-4 4-5 5-12 6-7 6-11 7-8 8-9 9-10 10-11 12-13 13-14
14-15 14-19 15-16 16-17 17-18 17-20 18-19 20-21 20-24 21-22 22-23 23-24
isolated ring systems :
containing 1 : 6 : 14 : 20 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 12:30:39 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     15 TO ITERATE

100.0% PROCESSED       15 ITERATIONS                                 6 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:           68 TO      532
PROJECTED ANSWERS:               6 TO      266

L2            6 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 12:30:42 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    371 TO ITERATE

100.0% PROCESSED      371 ITERATIONS                                96 ANSWERS
SEARCH TIME: 00.00.01

L3           96 SEA SSS FUL L1

=> s l3 and caplus/lc
      47569457 CAPLUS/LC
L4           93 L3 AND CAPLUS/LC

=> s l3 not l4
L5            3 L3 NOT L4

=> d l5 1-3
```

L5 ANSWER 1 OF 3 REGISTRY COPYRIGHT 2005 ACS on STN
RN 543744-81-6 REGISTRY
ED Entered STN: 07 Jul 2003
CN 1H-Pyrazole-5-carboxamide, N-[2-fluoro-4-[2-[(methylamino)methyl]-1H-imidazol-1-yl]phenyl]-1-(4-methoxyphenyl)-3-(methylsulfonyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H23 F N6 O4 S
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 2 OF 3 REGISTRY COPYRIGHT 2005 ACS on STN
RN 540510-35-8 REGISTRY
ED Entered STN: 01 Jul 2003
CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminoiminomethyl)-4-hydroxyphenyl]-N-[2-fluoro-4-[2-[(methylamino)methyl]-1H-imidazol-1-yl]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H20 F4 N8 O2
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 3 OF 3 REGISTRY COPYRIGHT 2005 ACS on STN
RN 385832-97-3 REGISTRY
ED Entered STN: 24 Jan 2002
CN 1H-Pyrazole-5-carboxamide, 1-[3-(5-amino-1,3,4-thiadiazol-2-yl)phenyl]-N-[2-fluoro-4-(2-methyl-1H-imidazol-1-yl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H16 F4 N8 O S
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	172.74	172.95

FILE 'CAPLUS' ENTERED AT 12:32:41 ON 10 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 10 Aug 2005 VOL 143 ISS 7
FILE LAST UPDATED: 9 Aug 2005 (20050809/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

L6 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:791919 CAPLUS
DOCUMENT NUMBER: 141:342889
TITLE: SAR and factor IXa crystal structure of a dual inhibitor of factors IXa and Xa
AUTHOR(S): Smallheer, Joanne M.; Alexander, Richard S.; Wang, Jianmin; Wang, Shuaige; Nakajima, Suanne; Rossi, Karen A.; Smallwood, Angela; Barbera, Frank; Burdick, Debra; Luettgen, Joseph M.; Knabb, Robert M.; Wexler, Ruth R.; Jadhav, Prabhakar K.
CORPORATE SOURCE: Bristol-Myers Squibb Company, Princeton, NJ, 08543-5400, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(21), 5263-5267
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 141:342889

AB Modifications to the P4 moiety and pyrazole C3 substituent of factor Xa inhibitor SN-429 provided several new compds., which are 5-10 nM inhibitors of factor IXa. An x-ray crystal structure of one example complexed to factor IXa shows that these compds. adopt a similar binding mode to that previously observed with pyrazole inhibitors in the factor Xa active site both with regard to how the inhibitor binds and the position of Tyr99.

IT 848394-00-3P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pyrazole compds. preparation, crystal structure, and dual inhibition of factors IXa and Xa)
RN 848394-00-3 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminoiminomethyl)phenyl]-N-[4-(1H-imidazol-1-yl)phenyl]-3-(trifluoromethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 209956-75-2
CMF C21 H16 F3 N7 O



L6 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CM 2

CRN 76-05-1
CMF C2 H F3 O2

IT 209956-75-2P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(pyrazole compds. preparation, crystal structure, and dual inhibition of factors IXa and Xa)
RN 209956-75-2 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminoiminomethyl)phenyl]-N-[4-(1H-imidazol-1-yl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



IT 209955-42-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(pyrazole compds. preparation, crystal structure, and dual inhibition of factors IXa and Xa)
RN 209955-42-0 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-(3-cyanophenyl)-N-[4-(1H-imidazol-1-yl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:566937 CAPLUS
DOCUMENT NUMBER: 142:219198
TITLE: Discovery of 1-(3'-Aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4-[(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide Hydrochloride (Razaxaban), a Highly Potent, Selective, and Orally Bioavailable Factor Xa Inhibitor
AUTHOR(S): Quan, Mimi L.; Lam, Patrick Y. S.; Han, Qi; Pinto, Donald J. P.; He, Ming Y.; Li, Renhua; Ellis, Christopher D.; Clark, Charles G.; Teleha, Christopher A.; Sun, Jung-Hui; Alexander, Richard S.; Bai, Steve; Luettgen, Joseph M.; Knabb, Robert M.; Wong, Pancras C.; Wexler, Ruth R.
CORPORATE SOURCE: Discovery Chemistry Pharmaceutical Research Institute, Bristol-Myers Squibb Co., Princeton, NJ, 08543-5400, USA
SOURCE: Journal of Medicinal Chemistry (2005), 48(6), 1729-1744
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Modification of a series of pyrazole factor Xa inhibitors to incorporate an aminobenzisoxazole as the P1 ligand resulted in compds. with improved selectivity for factor Xa relative to trypsin and plasma kallikrein. Further optimization of the P4 moiety led to compds. with enhanced permeability and reduced protein binding. The SAR and pharmacokinetic profile of this series of compds. is described. These efforts culminated in 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4-[(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxamide (I), a potent, selective, and orally bioavailable inhibitor of factor Xa. On the basis of its excellent in vitro potency and selectivity profile, high free fraction in human plasma, good oral bioavailability, and in vivo efficacy in antithrombotic models, the HCl salt of this compound was selected for clin. development as razaxaban (DPC 906, BMS-561389).

IT **405940-74-1P 540510-45-0P 540510-49-4P**
754193-49-2P 754193-50-5P 754193-51-6P
754193-52-7P 855869-81-7P 855869-83-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of razaxaban and related compds. as potent, selective, and orally bioavailable factor Xa inhibitors)

RN 405940-74-1 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-(3-cyano-4-fluorophenyl)-N-[4-[2-[(dimethylamino)methyl]-1H-imidazol-1-yl]-2-fluorophenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 540510-45-0 CAPLUS
CN Carbamic acid, [[1-[4-[[[1-(3-cyano-4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]carbonyl]amino]-3-fluorophenyl]-1H-imidazol-2-yl]methyl]methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 540510-49-4 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-(3-cyano-4-fluorophenyl)-N-[4-[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-1H-imidazol-1-yl]-2-fluorophenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 754193-52-7 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-(3-cyano-4-fluorophenyl)-N-[2-fluoro-4-[2-(1-pyrrolidinylmethyl)-1H-imidazol-1-yl]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 855869-81-7 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-(3-cyano-4-fluorophenyl)-N-[2-cyano-4-(2-methyl-1H-imidazol-1-yl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 855869-83-9 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-(3-cyano-4-fluorophenyl)-N-[2-methoxy-4-(2-



RN 754193-49-2 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-(3-cyano-4-fluorophenyl)-N-[2-fluoro-4-(2-methyl-1H-imidazol-1-yl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 754193-50-5 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-(3-cyano-4-fluorophenyl)-N-[4-(2-ethyl-1H-imidazol-1-yl)-2-fluorophenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 754193-51-6 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-(3-cyano-4-fluorophenyl)-N-[2-fluoro-4-[2-(1-methylethyl)-1H-imidazol-1-yl]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

methyl-1H-imidazol-1-yl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:20490 CAPLUS
DOCUMENT NUMBER: 140:77148
TITLE: Preparation of N-[4-(thiooxoheterocyclyl)phenyl]-2-phenyl-2H-pyrazole-3-carboxamides and corresponding imino-heterocyclyl derivatives as inhibitors of the coagulation factors Xa and/or VIIa for treating thrombosis
INVENTOR(S): Cezanne, Bertram; Dorsch, Dieter; Mederski, Werner; Tsaklakidis, Christos; Gleitz, Johannes; Barnes, Christopher
PATENT ASSIGNEE(S): Merck Patent Gmbh, Germany
SOURCE: PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004002477	A1	20040108	WO 2003-EP5898	20030605
WO 2004002477	C1	20040415		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10229070	A1	20040115	DE 2002-10229070	20020628
CA 2491271	AA	20040108	CA 2003-2491271	20030605
EP 1517685	A1	20050330	EP 2003-732540	20030605
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:			DE 2002-10229070	A 20020628
			WO 2003-EP5898	W 20030605

OTHER SOURCE(S): MARPAT 140:77148
GI



AB Title compds. [I; D = (N-, O-, S-interrupted) (substituted) C3-4 alkylene; M = Ph, aromatic heterocyclyl; R1, R2 = H, halo, (branched) (interrupted) (substituted) alkyl, NO2, cyano, OR3, N(R3)2, CO2R3, CON(R3)2, C(:S)N(R3)2, etc.; R3 = H, (branched) (interrupted) (substituted) alkyl, etc.; W = (substituted) (bi)cyclic aromatic (hetero)cyclyl; X = CONR3,

L6 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CONR3C(R4)2, C(R4)2NR3, etc.; R4 = H, (branched) (interrupted) (substituted) alkyl; Y = alkylene, cycloalkylene, heterodiyl, aryldiyl; T = (substituted) (bi)cyclic arom. heterocyclyl], were prepd. Thus, 333 mg (3-[5-(4-[2-iminopyrrolidin-1-yl]phenylcarbamoyl]-3-trifluoromethylpyrazol-1-yl]benzyl)carbamic acid tert-Bu ester (prepn. given) in EtOH was treated with HCl in ether to give 289 mg N-[4-(2-iminopyrrolidin-1-yl)phenyl]-1-(3-aminomethylphenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide. The latter gave affinity to the receptor Xa with IC50 = 9,6·10-9 M and to the receptor VIIa with IC50 = 2,3·10-8 M.

IT **640288-22-8P 640288-23-9P 640288-24-0P 640288-25-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (thiooxoheterocyclylphenyl)(phenylpyrazole)carboxamides and corresponding imino-heterocyclyl derivs. as inhibitors of the coagulation factors Xa and/or VIIa for treating thrombosis)

RN 640288-22-8 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminocarbonyl)phenyl]-N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 640288-23-9 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminocarbonyl)phenyl]-N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)-3-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 640288-24-0 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminocarbonyl)phenyl]-N-[4-[2-(cyanoamino)-4,5-dihydro-1H-imidazol-1-yl]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 640288-25-1 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminocarbonyl)phenyl]-N-[4-[2-(cyanoimino)-3-methyl-1-imidazolidinyl]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L6 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:454070 CAPLUS
DOCUMENT NUMBER: 139:36526
TITLE: Preparation of imidazolylphenylpyrazolopyridinones as factor Xa inhibitors
INVENTOR(S): Quan, Mimi L.; Wexler, Ruth R.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 421 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003047520	A2	20030612	WO 2002-US38331	20021126
WO 2003047520	A3	20040115		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003212054	A1	20031113	US 2002-304810	20021126
EP 1450800	A2	20040901	EP 2002-791349	20021126
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				

PRIORITY APPLN. INFO.: US 2001-337051P P 20011204
WO 2002-US38331 W 20021126

OTHER SOURCE(S): MARPAT 139:36526
GI



I

AB Imidazolylphenylpyrazolopyridinones were prepared as factor Xa inhibitors with Ki ≤ 10 μM. Thus, the imidazolylphenylpyrazolopyridinone I was prepared from 4-IC6H4NH2, Br(CH2)4COCl, 4-MeOC6H4NHNH2.HCl, and 2-(N-benzyloxycarbonyl-N-methylaminomethyl)-1H-imidazole in a multistep

L6 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 543744-29-2 CAPLUS
CN 1H-Pyrazole-3,5-dicarboxamide, N5-[2-fluoro-4-[2-[[methyl(methylsulfonyl)amino]methyl]-1H-imidazol-1-yl]phenyl]-1-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 543744-30-5 CAPLUS
CN 1H-Pyrazole-3,5-dicarboxamide, N5-[2-fluoro-4-[2-[[methyl(methylsulfonyl)amino]methyl]-1H-imidazol-1-yl]phenyl]-1-(4-methoxyphenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 543744-29-2
CMF C24 H24 F N7 O5 S

L6 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
synthesis.
IT 543744-27-0P 543744-28-1P 543744-29-2P
543744-30-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazolylphenylpyrazolopyridinones as factor Xa inhibitors)
RN 543744-27-0 CAPLUS
CN 1H-Pyrazole-5-carboxamide, N-[2-fluoro-4-[2-[[methyl(methylsulfonyl)amino]methyl]-1H-imidazol-1-yl]phenyl]-1-(4-methoxyphenyl)-3-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 543744-28-1 CAPLUS
CN 1H-Pyrazole-5-carboxamide, N-[2-fluoro-4-[2-[[methyl(methylsulfonyl)amino]methyl]-1H-imidazol-1-yl]phenyl]-1-(4-methoxyphenyl)-3-(methylsulfonyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 543744-27-0
CMF C24 H25 F N6 O6 S2



L6 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

IT 540510-45-0P 543744-76-9P 543744-80-5P
543744-82-7P 543744-85-0P 543744-86-1P
543744-87-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazolylphenylpyrazolopyridinones as factor Xa inhibitors)
RN 540510-45-0 CAPLUS
CN Carbamic acid, [[1-[4-[[[1-(3-cyano-4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]carbonyl]amino]-3-fluorophenyl]-1H-imidazol-2-yl]methyl]methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 543744-76-9 CAPLUS
CN Carbamic acid, [[1-[4-[[[1-(3-cyano-4-fluorophenyl)-3-(methylsulfonyl)-1H-pyrazol-5-yl]carbonyl]amino]-3-fluorophenyl]-1H-imidazol-2-yl]methyl]methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 543744-80-5 CAPLUS
CN Carbamic acid, [[1-[3-fluoro-4-[[[1-(4-methoxyphenyl)-3-(methylsulfonyl)-1H-pyrazol-5-yl]carbonyl]amino]phenyl]-1H-imidazol-2-yl]methyl]methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)





RN 543744-86-1 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-[[[2-fluoro-4-[2-[(methylamino)methyl]-1H-imidazol-1-yl]phenyl]amino]carbonyl]-1-(4-methoxyphenyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 543744-87-2 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-[[[2-fluoro-4-[2-[[methyl(methylsulfonyl)amino]methyl]-1H-imidazol-1-yl]phenyl]amino]carbonyl]-1-(4-methoxyphenyl)-, methyl ester (9CI) (CA INDEX NAME)

RN 543744-82-7 CAPLUS
CN 1H-Pyrazole-5-carboxamide, N-[2-fluoro-4-[2-[(methylamino)methyl]-1H-imidazol-1-yl]phenyl]-1-(4-methoxyphenyl)-3-(methylsulfonyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 543744-81-6
CMF C23 H23 F N6 O4 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 543744-85-0 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-[[[2-fluoro-4-[2-[[methyl[(phenylmethoxy)carbonyl]amino]methyl]-1H-imidazol-1-yl]phenyl]amino]carbonyl]-1-(4-methoxyphenyl)-, methyl ester (9CI) (CA INDEX NAME)



L6 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:454067 CAPLUS
DOCUMENT NUMBER: 139:36524
TITLE: Preparation of novel N-[4-(1H-imidazol-1-yl)-2-fluorophenyl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamides as factor Xa inhibitors
INVENTOR(S): Quan, Mimi L.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003047517	A2	20030612	WO 2002-US38168	20021126
WO 2003047517	A3	20040226		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003144287	A1	20030731	US 2002-302184	20021122
US 6730689	B2	20040504		
EP 1460996	A2	20040929	EP 2002-789922	20021126
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
PRIORITY APPLN. INFO.:			US 2001-336972P	P 20011204
			WO 2002-US38168	W 20021126

OTHER SOURCE(S): MARPAT 139:36524
GI

L6 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



I



II

AB N-[4-(1H-imidazol-1-yl)-2-fluorophenyl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamides of formula I [R = H, alkyl; R1 = H, acyl, etc.] and derivs. thereof are prepared which are useful as inhibitors of factor Xa. Thus, II was prepared in several steps. The prepared compds. had Ki values of ≤ 10 μM against human factor Xa.

IT **540510-36-9P 540510-43-8P**
RL: DGN (Diagnostic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazolylphenyl pyrazolecarboxamide derivs. as factor Xa inhibitors)

RN 540510-36-9 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminoiminomethyl)-4-hydroxyphenyl]-N-[2-fluoro-4-[2-[(methylamino)methyl]-1H-imidazol-1-yl]phenyl]-3-(trifluoromethyl)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 540510-35-8
CMF C23 H20 F4 N8 O2

L6 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 540510-43-8 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminoiminomethyl)-4-hydroxyphenyl]-N-[4-[2-[(dimethylamino)methyl]-1H-imidazol-1-yl]-2-fluorophenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



IT **405940-74-1P 540510-45-0P 540510-49-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazolylphenyl pyrazolecarboxamide derivs. as factor Xa inhibitors)

RN 405940-74-1 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-(3-cyano-4-fluorophenyl)-N-[4-[2-[(dimethylamino)methyl]-1H-imidazol-1-yl]-2-fluorophenyl]-3-

L6 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 540510-45-0 CAPLUS
CN Carbamic acid, [[1-[4-[[[1-(3-cyano-4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]carbonyl]amino]-3-fluorophenyl]-1H-imidazol-2-yl]methyl]methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 540510-49-4 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-(3-cyano-4-fluorophenyl)-N-[4-[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-1H-imidazol-1-yl]-2-fluorophenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L6 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L6 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:240767 CAPLUS
DOCUMENT NUMBER: 136:281142
TITLE: Efficient process for the preparation of a factor Xa inhibitor
INVENTOR(S): Sunkara, Hari Babu; Yang, Yali
PATENT ASSIGNEE(S): E. I. Du Pont de Nemours & Co., USA
SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002024690	A2	20020328	WO 2001-US28406	20010912
WO 2002024690	C1	20020808		
WO 2002024690	A3	20030925		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2424576	AA	20020328	CA 2001-2424576	20010912
AU 2001092612	A5	20020402	AU 2001-92612	20010912
EP 1366045	A2	20031203	EP 2001-972987	20010912
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004529853	T2	20040930	JP 2002-529100	20010912
EE 200300116	A	20050415	EE 2003-116	20010912
BR 2001014102	A	20050419	BR 2001-14102	20010912
US 2002061917	A1	20020523	US 2001-960040	20010921
US 6667332	B2	20031223		
TW 593314	B	20040621	TW 2001-90123363	20010921
NO 2003001308	A	20030507	NO 2003-1308	20030321
US 2003212117	A1	20031113	US 2003-431265	20030507
US 6747158	B2	20040608		
BG 107813	A	20040130	BG 2003-107813	20030513
US 2004198787	A1	20041007	US 2004-826099	20040415

PRIORITY APPLN. INFO.:

US 2000-234622P	P	20000922
WO 2001-US28406	W	20010912
US 2001-960040	A3	20010921
US 2003-431265	A3	20030507

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to the process for the preparation of the compound

L6 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
I.HCl, useful as a factor Xa inhibitor, from compd. II and intermediates useful therein. The improved process involves reacting unpurified II with maleic acid in EtOAc, pptg. the resulting compd. I by adding BuCl to the reaction mixt., reacting I with HONHCOMe in a solvent in the presence of K2CO3, Na2CO3, KHCO3, NaHCO3, KF, NaOH, or KOH, and contacting the resulting product with HCl.

IT **405940-74-1P 405940-75-2P**
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(precursor; aminomethylimidazolophenylaminocarbonylbenzisoxazolyltrifluoromethylpyrazole factor Xa inhibitor manuf)

RN 405940-74-1 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-(3-cyano-4-fluorophenyl)-N-[4-[2-[(dimethylamino)methyl]-1H-imidazol-1-yl]-2-fluorophenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 405940-75-2 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-(3-cyano-4-fluorophenyl)-N-[4-[2-[(dimethylamino)methyl]-1H-imidazol-1-yl]-2-fluorophenyl]-3-(trifluoromethyl)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 405940-74-1
CMF C24 H18 F5 N7 O



L6 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



L6 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:10466 CAPLUS
DOCUMENT NUMBER: 136:85809
TITLE: Preparation of heteroarylphenyl substituted factor Xa inhibitors for treatment of thromboembolic disorders
INVENTOR(S): Pinto, Donald J. P.; Quan, Mimi L.; Woerner, Francis J.
PATENT ASSIGNEE(S): Dupont Pharmaceuticals Company, USA
SOURCE: PCT Int. Appl., 146 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000647	A1	20020103	WO 2001-US20112	20010622
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2409762	AA	20020103	CA 2001-2409762	20010622
US 2002103202	A1	20020801	US 2001-887936	20010622
US 6599926	B2	20030729		
EP 1296977	A1	20030402	EP 2001-946698	20010622
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004501913	T2	20040122	JP 2002-505771	20010622
PRIORITY APPLN. INFO.:			US 2000-214033P P	20000623
			WO 2001-US20112 W	20010622

OTHER SOURCE(S): MARPAT 136:85809
GI

L6 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT **385832-92-8P**, 1-[3-(2-Oxo-1,3,4-triazol-5-yl)phenyl]-3-trifluoromethyl-5-[[[4-[2-(N,N-dimethylamino)methylimidazol-1-yl]-2-fluorophenyl]amino]carbonyl]pyrazole **385832-93-9P**, 1-[3-(2-Oxo-1,3,4-triazol-5-yl)phenyl]-3-trifluoromethyl-5-[[[4-[2-(N,N-dimethylaminomethyl)imidazol-1-yl]-2-fluorophenyl]amino]carbonyl]pyrazole trifluoroacetic acid salt **385832-98-4P**, 1-[3-(2-Amino-1,3,4-thiadiazol-5-yl)phenyl]-3-trifluoromethyl-5-[[[4-(2-methylimidazol-1-yl)-2-fluorophenyl]amino]carbonyl]pyrazole trifluoroacetic acid salt **385833-29-4P**, 1-[3-(2-Oxo-1,3,4-triazol-5-yl)phenyl]-3-trifluoromethyl-5-[[[4-(2-methylimidazol-1-yl)-2-fluorophenyl]amino]carbonyl]pyrazole
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heteroarylphenyl-substituted pyrazolamides as factor Xa
inhibitors for treatment of thromboembolic disorders)

RN 385832-92-8 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[3-(2,5-dihydro-5-oxo-1H-1,2,4-triazol-3-yl)phenyl]-N-[4-[2-[(dimethylamino)methyl]-1H-imidazol-1-yl]-2-fluorophenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 385832-93-9 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[3-(2,5-dihydro-5-oxo-1H-1,2,4-triazol-3-

L6 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



AB Title compds. I, II, and III [wherein ring D1 = pyridine, pyrazine, pyridazine, or pyrimidine substituted with 1 Ra and 0-1 Rb; ring D2 = 5-membered heteroarom. ring substituted with 1 Ra and 0-1 Rb; E = O, 3S, or NRc; ring D3 = 5-membered heteroarom. ring substituted with 1 Ra and 0-1 Rb; R, Ra, and Rb = H, alkyl, halo, OH, alkoxy, CN, (un)substituted carboximidamido, (alkyl)amino, OCF3, etc.; Rc = H, alkyl, alkoxy, (un)substituted (alkyl)amino, OCF3, etc.; G = absent or (CH2)1-3, (CH2)0-2CO(CH2)0-2, (CH2)0-2O(CH2)0-2, (CH2)0-2NH(CH2)0-2, (CH2)0-2SOp(CH2)0-2, etc.; p = 0-2; G1 = (un)substituted (CH2)1-5, (CH2)0-2CH=CH(CH2)0-2, (CH2)0-2C.tplbond.C(CH2)0-2, (CH2)uCO(CH2)w, (CH2)uOCO(CH2)w, (CH2)uCO2(CH2)w, (CH2)uNH(CH2)w, etc.; u + w = 0-4; G2 = Ph, naphthyl, or heteroaryl; M = isoxazoline, pyrazoline, isothiazoline, triazoline tetrazoline, Ph, or substituted 5-6 membered heteroaryl; and pharmaceutically acceptable salts or prodrugs thereof] were prepared as factor Xa inhibitors. For example, HCl gas was bubbled through

1-(3-cyanophenyl)-3-trifluoromethyl-5-[(2'-sulfonylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole in anhydrous EtOH to afford the ethoxyimidate intermediate. Addition of N-methylmorpholine to the crude product in dioxane, followed by cyclization with semicarbazide•HCl, gave the pyrazolamide IV. Some of the invention compds. inhibited factor Xa with Ki values of ≤ 10 μM. Thus, I are useful as anticoagulants for the treatment of thromboembolic disorders (no data).

IT **385832-94-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of heteroarylphenyl-substituted pyrazolamides as
factor Xa inhibitors for treatment of thromboembolic disorders)

RN 385832-94-0 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-(3-cyanophenyl)-N-[4-[2-[(dimethylamino)methyl]-1H-imidazol-1-yl]-2-fluorophenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

yl)phenyl]-N-[4-[2-[(dimethylamino)methyl]-1H-imidazol-1-yl]-2-fluorophenyl]-3-(trifluoromethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 385832-92-8
CMF C25 H21 F4 N9 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 385832-98-4 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[3-(5-amino-1,3,4-thiadiazol-2-yl)phenyl]-N-[2-fluoro-4-(2-methyl-1H-imidazol-1-yl)phenyl]-3-(trifluoromethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 385832-97-3
CMF C23 H16 F4 N8 O S

L6 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 385833-29-4 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[3-(2,5-dihydro-5-oxo-1H-1,2,4-triazol-3-yl)phenyl]-N-[2-fluoro-4-(2-methyl-1H-imidazol-1-yl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L6 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:338499 CAPLUS
DOCUMENT NUMBER: 134:348280
TITLE: Cyano compounds as factor Xa inhibitors
INVENTOR(S): Pinto, Donald J. P.
PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Company, USA
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001032628	A1	20010510	WO 2000-US30209	20001102
W: US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
US 6407256	B1	20020618	US 2000-686382	20001011
EP 1226123	A1	20020731	EP 2000-976822	20001102
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
PRIORITY APPLN. INFO.:			US 1999-163268P	P 19991103
			WO 2000-US30209	W 20001102

OTHER SOURCE(S): MARPAT 134:348280
GI



Ia

Ib



Ic



Id

AB The present application describes inhibitors of factor Xa which are cyano-pyrazole, cyano-triazole, cyano-imidazole, and cyano-pyrrole compds. of Formulas Ia, Ib, Ic, and Id: or pharmaceutically acceptable salt forms thereof. Markush structures and exemplary compds. of the invention are given (no data).

L6 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
IT **338946-83-1 338946-84-2 338946-87-5**
338946-88-6
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyano compds. as factor Xa inhibitors)
RN 338946-83-1 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminomethyl)phenyl]-3-cyano-N-[4-(2-methyl-1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 338946-84-2 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminomethyl)phenyl]-3-cyano-N-[4-[2-(dimethylamino)-1H-imidazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 338946-87-5 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminomethyl)phenyl]-3-cyano-N-[2-fluoro-4-(2-methyl-1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 338946-88-6 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminomethyl)phenyl]-3-cyano-N-[4-[2-(dimethylamino)-1H-imidazol-1-yl]-2-fluorophenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
IT 209955-42-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of azoles as Factor Xa inhibitors)
RN 209955-42-0 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-(3-cyanophenyl)-N-[4-(1H-imidazol-1-yl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



IT 209954-63-2P 209954-64-3P 209955-43-1P
209956-30-9P 209956-31-0P 209956-75-2P
209956-76-3P 209957-83-5P 209957-98-2P
209957-99-3P 209958-28-1P 209958-29-2P
256512-19-3P 256512-30-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of azoles as Factor Xa inhibitors)
RN 209954-63-2 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminoiminomethyl)phenyl]-N-[4-(1H-imidazol-1-yl)phenyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 209954-64-3 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminoiminomethyl)phenyl]-N-[4-(1H-imidazol-1-yl)phenyl]-3-methyl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

L6 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:83115 CAPLUS
DOCUMENT NUMBER: 132:137392
TITLE: Preparation of azoles as Factor Xa inhibitors.
INVENTOR(S): Pinto, Donald Joseph Phillip; Pruitt, James Russell; Cacciola, Joseph; Fevig, John Matthew; Han, Qi; Orwat, Michael James; Quan, Mimi Lifen; Rossi, Karen Anita
PATENT ASSIGNEE(S): Dupont Pharmaceuticals Co., USA
SOURCE: U.S., 152 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6020357	A	20000201	US 1997-995834	19971222
US 6548512	B1	20030415	US 2000-492708	20000127
PRIORITY APPLN. INFO.:			US 1996-33437P P	19961223
			US 1997-50304P P	19970620
			US 1997-995834 A3	19971222

OTHER SOURCE(S): MARPAT 132:137392
GI



AB Title compds. [I; ring M contains, in addition to J, 0-3 N atoms; J = N, NH;
D = CN, C(:NR8)NR7R9, C(O)NR7R8, etc.; E = (un)substituted Ph, pyridyl, pyrimidinyl, etc.; DEG = R-substituted pyridyl; R = H, halo, CF3, etc.; G = absent, NHCH2, OCH2, etc.; Z = C1-4 alkylene, (CH2)rO(CH2)r, etc.; R1a, R1b = absent, NMe, OMe, etc.; A = (un)substituted C3-10 carbocyclic residue, 5-10 membered heterocyclic containing from 1-4 heteroatoms selected from N, O, and S; B = (un)substituted C3-10 carbocyclic residue, 5-10 membered heterocyclic containing from 1-4 heteroatoms selected from N, O, and S, etc.; R7 = H, OH, C1-6 alkyl, etc.; R8, R9 = H, C1-6 alkyl, (CH2)nPh; n = 0-3; r = 0-3; s = 0-2; with provisos], useful as inhibitors of factor Xa, were prepared and formulated. Thus, treatment of 4-[o-(tert-BuSO2)phenyl]aniline with Me3Al/hexane in CH2Cl2 followed by the addition of Me 1-(3-cyanophenyl)imidazol-2-ylcarboxylate (preparation described), and the Pinner reaction of the resulting intermediate afforded 1-(3-amidinophenyl)-2-[(2'-aminosulfonyl-1,1'-biphen-4-yl)aminocarbonyl]imidazole. Several I showed Ki ≤10 μM against Factor Xa and thrombin.

L6 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CM 1

CRN 209954-63-2
CMF C21 H19 N7 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 209955-43-1 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-(3-cyanophenyl)-N-[4-(1H-imidazol-1-yl)phenyl]-3-(trifluoromethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 209955-42-0
CMF C21 H13 F3 N6 O



L6 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 209956-30-9 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminoiminomethyl)phenyl]-3-methyl-N-[4-(2-methyl-1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 209956-31-0 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminocarbonyl)phenyl]-3-methyl-N-[4-(2-methyl-1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 209956-75-2 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminoiminomethyl)phenyl]-N-[4-(1H-imidazol-1-yl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 209956-76-3 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminoiminomethyl)phenyl]-N-[4-(1H-imidazol-1-yl)phenyl]-3-(trifluoromethyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 209956-75-2
CMF C21 H16 F3 N7 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 209957-83-5 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-4-(2-methyl-1H-imidazol-1-yl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 209957-98-2 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminomethyl)phenyl]-3-ethyl-N-[2-fluoro-4-[2-(methylsulfonyl)-1H-imidazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 209957-99-3 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminomethyl)phenyl]-3-ethyl-N-[2-fluoro-4-[2-(methylsulfonyl)-1H-imidazol-1-yl]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 209957-98-2
CMF C23 H23 F N6 O3 S



L6 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 209958-28-1 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminomethyl)phenyl]-N-[4-[5-[(methoxyamino)carbonyl]-1H-imidazol-1-yl]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 209958-29-2 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminomethyl)phenyl]-N-[4-[5-[(methoxyamino)carbonyl]-1H-imidazol-1-yl]phenyl]-3-(trifluoromethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 209958-28-1
CMF C23 H20 F3 N7 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 256512-19-3 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminoiminomethyl)phenyl]-N-[4-(1H-imidazol-1-yl)phenyl]-3-(trifluoromethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 209956-75-2
CMF C21 H16 F3 N7 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 256512-30-8 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-4-(2-methyl-1H-imidazol-1-yl)phenyl]-3-(trifluoromethyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 209957-83-5
CMF C22 H18 F4 N6 O



RN 209960-28-1 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-(3-cyanophenyl)-N-(3-fluoro-4-(2-methyl-1H-imidazol-1-yl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 209960-40-7 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-(3-cyanophenyl)-3-ethyl-N-[2-fluoro-4-(2-(methylsulfonyl)-1H-imidazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 209960-72-5 CAPLUS
CN 1H-Imidazole-5-carboxylic acid, 1-[4-[[[1-(3-cyanophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]carbonyl]amino]phenyl]-, butyl ester (9CI) (CA INDEX NAME)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

IT 209958-75-8P 209959-49-9P 209960-28-1P
209960-40-7P 209960-72-5P 209960-73-6P
209960-74-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of azoles as Factor Xa inhibitors)

RN 209958-75-8 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-(3-cyanophenyl)-N-[4-(1H-imidazol-1-yl)phenyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 209959-49-9 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-(3-cyanophenyl)-3-methyl-N-[4-(2-methyl-1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 209960-73-6 CAPLUS
CN 1H-Imidazole-5-carboxylic acid, 1-[4-[[[1-(3-cyanophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 209960-74-7 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-(3-cyanophenyl)-N-[4-[5-[(methoxyamino)carbonyl]-1H-imidazol-1-yl]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:421659 CAPLUS
DOCUMENT NUMBER: 131:58820
TITLE: Preparation of nitrogen heteroaromatics as blood coagulation factor Xa inhibitors
INVENTOR(S): Galemmo, Robert A., Jr.; Pinto, Donald J. P.; Bostrom, Lori L.; Rossi, Karen Anita
PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Company, USA
SOURCE: PCT Int. Appl., 237 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9932454	A1	19990701	WO 1998-US26427	19981211
W: AU, BR, CA, CN, CZ, EE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2314401	AA	19990701	CA 1998-2314401	19981211
AU 9917244	A1	19990712	AU 1999-17244	19981211
BR 9813835	A	20001010	BR 1998-13835	19981211
EP 1042299	A1	20001011	EP 1998-962082	19981211
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
JP 2001526268	T2	20011218	JP 2000-525391	19981211
ZA 9811517	A	20000615	ZA 1998-11517	19981215
US 6271237	B1	20010807	US 1998-217336	19981221
US 2002016326	A1	20020207	US 2001-833302	20010412
US 6548525	B2	20030415		

PRIORITY APPLN. INFO.: US 1997-68491P P 19971222
US 1997-996447 A 19971222
US 1998-101075P P 19980918
WO 1998-US26427 W 19981211
US 1998-217336 A3 19981221

OTHER SOURCE(S): MARPAT 131:58820
GI



II

L6 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

AB DEG(CH2)sMZAB [I; D = cyano, amino(alkyl), amidino, etc.; E = (un)substituted phenylene, -pyridinediyl, -pyrimidinediyl, etc.; G = bond, NHCH2, OCH2, SCH2; M = (un)substituted pyrrolylene, -di-, -tri-, or -tetrazolylene; Z = (heteroatom-interrupted)(oxo)alkylene, oxyalkylene, alkyleneoxy, etc.; A = (un)substituted carbocyclic residue (sic) or -heterocyclylene; B = amino(alkyl), amidino, ureido, (un)substituted carbocyclic residue, etc.; s = 0-2] were prepared Thus, 2-hydrazino-5-methoxybenzoic acid was cyclocondensed with MeCOCH2C(:NOMe)CO2Et (preparation each given) and the product converted in 3 steps to 3-methyl-1-(2-azidomethyl-4-methoxyphenyl)-1H-pyrazole-5-carboxylic acid which was amidated by 4-(H2N)C6H4C6H4(CO2NHCMe3)-2 to give, in 2 addnl. steps, title compound II. Data for biol. activity of I were given.

IT 228257-96-3P 228257-97-4P 228257-98-5P
228257-99-6P 228258-00-2P 228258-01-3P
228258-02-4P 228258-03-5P 228258-04-6P
228258-05-7P 228258-06-8P 228258-07-9P
228258-08-0P 228258-09-1P 228258-10-4P
228258-11-5P 228258-12-6P 228258-13-7P
228258-14-8P 228258-15-9P 228258-16-0P
228258-17-1P 228258-18-2P 228258-19-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of nitrogen heteroaroms. as blood coagulation factor Xa inhibitors)

RN 228257-96-3 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[2-(aminomethyl)-4-methoxyphenyl]-3-methyl-N-[4-(2-methyl-1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 228257-97-4 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[2-(aminomethyl)-4-methoxyphenyl]-3-ethyl-N-[4-(2-methyl-1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 228257-98-5 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[2-(aminomethyl)-4-methoxyphenyl]-N-[4-(2-methyl-1H-imidazol-1-yl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 228257-99-6 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[4-methoxy-2-[(methylamino)methyl]phenyl]-3-methyl-N-[4-(2-methyl-1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 228258-00-2 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 3-ethyl-1-[4-methoxy-2-[(methylamino)methyl]phenyl]-N-[4-(2-methyl-1H-imidazol-1-yl)phenyl]-

L6 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(9CI) (CA INDEX NAME)



RN 228258-01-3 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[4-methoxy-2-[(methylamino)methyl]phenyl]-N-[4-(2-methyl-1H-imidazol-1-yl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 228258-02-4 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[2-(aminomethyl)-4-methoxyphenyl]-3-methyl-N-[4-(5-methyl-1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 228258-03-5 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[2-(aminomethyl)-4-methoxyphenyl]-3-ethyl-N-[4-(5-methyl-1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 228258-04-6 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[2-(aminomethyl)-4-methoxyphenyl]-N-[4-(5-methyl-1H-imidazol-1-yl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 228258-05-7 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[4-methoxy-2-[(methylamino)methyl]phenyl]-3-methyl-N-[4-(5-methyl-1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 228258-06-8 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 3-ethyl-1-[4-methoxy-2-[(methylamino)methyl]phenyl]-N-[4-(5-methyl-1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 228258-07-9 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[4-methoxy-2-[(methylamino)methyl]phenyl]-N-[4-(5-methyl-1H-imidazol-1-yl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 228258-08-0 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[2-(aminomethyl)-4-methoxyphenyl]-N-[2-fluoro-4-(2-methyl-1H-imidazol-1-yl)phenyl]-3-methyl- (9CI) (CA INDEX NAME)

L6 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 228258-09-1 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[2-(aminomethyl)-4-methoxyphenyl]-3-ethyl-N-[2-fluoro-4-(2-methyl-1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 228258-10-4 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[2-(aminomethyl)-4-methoxyphenyl]-N-[2-fluoro-4-(2-methyl-1H-imidazol-1-yl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 228258-11-5 CAPLUS
CN 1H-Pyrazole-5-carboxamide, N-[2-fluoro-4-(2-methyl-1H-imidazol-1-yl)phenyl]-1-[4-methoxy-2-[(methylamino)methyl]phenyl]-3-methyl- (9CI) (CA INDEX NAME)

L6 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 228258-12-6 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 3-ethyl-N-[2-fluoro-4-(2-methyl-1H-imidazol-1-yl)phenyl]-1-[4-methoxy-2-[(methylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 228258-13-7 CAPLUS
CN 1H-Pyrazole-5-carboxamide, N-[2-fluoro-4-(2-methyl-1H-imidazol-1-yl)phenyl]-1-[4-methoxy-2-[(methylamino)methyl]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 228258-14-8 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-(2-(aminomethyl)-4-methoxyphenyl]-N-[2-fluoro-

L6 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
4-(5-methyl-1H-imidazol-1-yl)phenyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 228258-15-9 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[2-(aminomethyl)-4-methoxyphenyl]-3-ethyl-N-[2-fluoro-4-(5-methyl-1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 228258-16-0 CAPLUS
CN 1H-Pyrazole-5-carboxamide,
1-[2-(aminomethyl)-4-methoxyphenyl]-N-[2-fluoro-
4-(5-methyl-1H-imidazol-1-yl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX
NAME)



RN 228258-17-1 CAPLUS
CN 1H-Pyrazole-5-carboxamide, N-[2-fluoro-4-(5-methyl-1H-imidazol-1-

L6 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L6 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
yl)phenyl]-1-[4-methoxy-2-[(methylamino)methyl]phenyl]-3-methyl- (9CI)
(CA INDEX NAME)



RN 228258-18-2 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 3-ethyl-N-[2-fluoro-4-(5-methyl-1H-imidazol-1-yl)phenyl]-1-[4-methoxy-2-[(methylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 228258-19-3 CAPLUS
CN 1H-Pyrazole-5-carboxamide, N-[2-fluoro-4-(5-methyl-1H-imidazol-1-

yl)phenyl]-1-[4-methoxy-2-[(methylamino)methyl]phenyl]-3-(trifluoromethyl)-
(9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS

L6 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:9820 CAPLUS
DOCUMENT NUMBER: 130:81510
TITLE: Preparation of phenylpyrazolecarboxamides as coagulation factor Xa inhibitors
INVENTOR(S): Galemmo, Robert Anthony, Jr.; Dominguez, Celia; Fevig,
John Matthew; Han, Qi; Lam, Patrick Yuk-sun; Pinto, Donald Joseph Philip; Pruitt, James Russell; Quan, Mimi Lifen
PATENT ASSIGNEE(S): The Du Pont Merck Pharmaceutical Company, USA
SOURCE: PCT Int. Appl., 259 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9857937	A2	19981223	WO 1998-US12681	19980618
WO 9857937	A3	19990318		
W: AU, BR, CA, CN, CZ, EE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
ZA 9805251	A	19991217	ZA 1998-5251	19980617
CA 2290982	AA	19981223	CA 1998-2290982	19980618
AU 9881503	A1	19990104	AU 1998-81503	19980618
US 5998424	A	19991207	US 1998-99752	19980618
EP 991625	A2	20000412	EP 1998-931355	19980618
EP 991625	B1	20050601		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
BR 9810151	A	20000808	BR 1998-10151	19980618
EE 9900584	A	20000815	EE 1999-584	19980618
SI 20208	C	20001031	SI 1998-20043	19980618
JP 2002507968	T2	20020312	JP 1999-504786	19980618
AT 296805	E	20050615	AT 1998-931355	19980618
US 6403620	B1	20020611	US 1999-393782	19990910
LV 12516	B	20010320	LV 1999-177	19991216
NO 9906316	A	19991217	NO 1999-6316	19991217
LT 4702	B	20000925	LT 1999-146	19991217
US 2003092740	A1	20030515	US 2002-150698	20020516
US 6602895	B2	20030805		

PRIORITY APPLN. INFO.:	US 1997-50219P	P	19970619
	US 1997-878885	A	19970619
	US 1998-76691P	P	19980227
	US 1998-99752	A3	19980618
	WO 1998-US12681	W	19980618
	US 1999-393782	A3	19990910

OTHER SOURCE(S): MARPAT 130:81510
GI



II

AB EZlM [I; E = halo, OH, alkyl, alkoxy, etc.; M = Z2ZAB; A = (un)substituted carbocyclylene, -heterocyclylene; B = H, Y, XY; X = alkylene, CO, O, (un)substituted NH, etc.; Y = amino(alkyl), substituted carbocyclyl, -heterocyclyl, etc.; Z = bond, (heteroatom- or functional group-interrupted) alkylene, etc.; Z1 = (un)substituted Ph, Z2 = N-containing heteroarylene, etc.] were prepared Thus, MeCOCH2C(:NOMe)CO2Et was cyclocondensed with PhNHNH2 and the product amidated by 4-(H2N)C6H4C6H4(SO2NHCMe3)-2 to give, after deprotection, title compound II.

Data for biol. activity of I were given.

IT **218630-58-1P 218630-59-2P 218630-60-5P**
218630-61-6P 218630-62-7P 218630-63-8P
218630-64-9P 218630-65-0P 218630-66-1P
218630-87-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenylpyrazolecarboxamides as coagulation factor Xa inhibitors)

RN 218630-58-1 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-(4-methoxyphenyl)-N-[4-(2-methyl-1H-imidazol-1-yl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 218630-59-2 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-(4-methoxyphenyl)-N-[4-(2-methyl-1H-imidazol-1-yl)phenyl]-3-(trifluoromethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 218630-58-1
CMF C22 H18 F3 N5 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 218630-60-5 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-(4-methoxyphenyl)-3-methyl-N-[4-(5-methyl-1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 218630-61-6 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-(4-methoxyphenyl)-3-methyl-N-[4-(4-methyl-1H-

imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 218630-62-7 CAPLUS
CN 1H-Imidazole-5-carboxylic acid, 1-[4-[[[1-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]carbonyl]amino]phenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 218630-63-8 CAPLUS
CN 1H-Imidazole-5-carboxylic acid, 1-[4-[[[1-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 218630-64-9 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-(4-methoxyphenyl)-N-[4-[5-[(methylamino)carbonyl]-1H-imidazol-1-yl]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 218630-65-0 CAPLUS
CN 1H-Pyrazole-5-carboxamide, N-[4-[5-(aminocarbonyl)-1H-imidazol-1-yl]phenyl]-1-(4-methoxyphenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 218630-66-1 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-(4-methoxyphenyl)-N-[4-[5-[[(methylsulfonyl)amino]carbonyl]-1H-imidazol-1-yl]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L6 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 218630-87-6 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-(4-methoxyphenyl)-3-methyl-N-[4-(2-methyl-1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:479506 CAPLUS
DOCUMENT NUMBER: 129:109090
TITLE: Preparation of nitrogen-containing heteroaromatics as factor Xa inhibitors
INVENTOR(S): Pinto, Donald Joseph Phillip; Pruitt, James Russell; Cacciola, Joseph; Fevig, John Matthew; Han, Qi; Orwat, Michael James; Quan, Mimi Lifen; Rossi, Karen Anita
PATENT ASSIGNEE(S): The Dupont Merck Pharmaceutical Co., USA
SOURCE: PCT Int. Appl., 438 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9828269	A1	19980702	WO 1997-US22895	19971215
W: AM, AU, AZ, BR, BY, CA, CN, CZ, EE, HU, IL, JP, KG, KR, KZ, LT, LV, MD, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, UA, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2275796	AA	19980702	CA 1997-2275796	19971215
AU 9856020	A1	19980717	AU 1998-56020	19971215
AU 730224	B2	20010301		
EP 946508	A1	19991006	EP 1997-952409	19971215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
EE 9900316	A	20000215	EE 1999-316	19971215
SI 20017	C	20000229	SI 1997-20082	19971215
CN 1246847	A	20000308	CN 1997-181852	19971215
BR 9714073	A	20000509	BR 1997-14073	19971215
JP 2001509145	T2	20010710	JP 1998-528845	19971215
ZA 9711586	A	19990701	ZA 1997-11586	19971223
TW 492971	B	20020701	TW 1997-86119637	19980203
NO 9902633	A	19990820	NO 1999-2633	19990601
NO 313190	B1	20020826		
MX 9905878	A	20000131	MX 1999-5878	19990622
LT 4673	B	20000725	LT 1999-76	19990622
LV 12430	B	20000720	LV 1999-99	19990730
PRIORITY APPLN. INFO.:			US 1996-769859 A	19961223
			US 1997-879944 A	19970620
			WO 1997-US22895 W	19971215

OTHER SOURCE(S): MARPAT 129:109090
GI

L6 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



AB The title compds. [I; ring M contains, in addition to J, 0-3 N atoms; J = N, NH; D = CN, C(:NR8)NR7R9, C(O)NR7R8, etc.; E = (un)substituted Ph, pyridyl, pyrimidinyl, etc.; DEG = R-substituted pyridyl; R = H, halo, CF3, etc.; G = absent, NHCH2, OCH2, etc.; Z = C1-4 alkylene, (CH2)rO(CH2)r, etc.; R1a, R1b = absent, NMe, OMe, etc.; A = (un)substituted C3-10 carbocyclic residue, 5-10 membered heterocyclic containing from 1-4 heteroatoms selected from N, O, and S; B = (un)substituted C3-10 carbocyclic residue, 5-10 membered heterocyclic containing from 1-4 heteroatoms selected from N, O, and S, etc.; R7 = H, OH, C1-6 alkyl, etc.; R8, R9 = H, C1-6 alkyl, (CH2)nPh; n = 0-3; r = 0-3; s = 0-2], useful as inhibitors of factor Xa, were prepared and formulated. Thus, treatment of 4-[o-(tert-BuSO2)phenyl]aniline with Me3Al/hexane in CH2C12 followed by the addition of Me 1-(3-cyanophenyl)imidazol-2-ylcarboxylate (preparation described), and the Pinner reaction of the resulting intermediate afforded the title compound II. A number of compds. I were found to exhibit a Ki of ≤ 10 μM against factor Xa. Some compds. I were evaluated and found to exhibit Ki of < 10 μM against thrombin.
IT **209955-42-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of nitrogen-containing heteroaroms. as factor Xa inhibitors)
RN 209955-42-0 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-(3-cyanophenyl)-N-[4-(1H-imidazol-1-yl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT **209954-63-2P 209954-64-3P 209955-43-1P**
209956-30-9P 209956-31-0P 209956-75-2P
209956-76-3P 209957-83-5P 209957-84-6P
209957-98-2P 209957-99-3P 209958-28-1P
209958-29-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of nitrogen-containing heteroaroms. as factor Xa inhibitors)
RN 209954-63-2 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminoiminomethyl)phenyl]-N-[4-(1H-imidazol-1-yl)phenyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 209954-64-3 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminoiminomethyl)phenyl]-N-[4-(1H-imidazol-1-yl)phenyl]-3-methyl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 209954-63-2
CMF C21 H19 N7 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 209955-43-1 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-(3-cyanophenyl)-N-[4-(1H-imidazol-1-yl)phenyl]-3-(trifluoromethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 209955-42-0
CMF C21 H13 F3 N6 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 209956-76-3 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminoiminomethyl)phenyl]-N-[4-(1H-imidazol-1-yl)phenyl]-3-(trifluoromethyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 209956-75-2
CMF C21 H16 F3 N7 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 209957-83-5 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-4-(2-methyl-1H-imidazol-1-yl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

RN 209956-30-9 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminoiminomethyl)phenyl]-3-methyl-N-[4-(2-methyl-1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 209956-31-0 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminocarbonyl)phenyl]-3-methyl-N-[4-(2-methyl-1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 209956-75-2 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminoiminomethyl)phenyl]-N-[4-(1H-imidazol-1-yl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 209957-84-6 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-4-(2-methyl-1H-imidazol-1-yl)phenyl]-3-(trifluoromethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 209957-83-5
CMF C22 H18 F4 N6 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 209957-98-2 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminomethyl)phenyl]-3-ethyl-N-[2-fluoro-4-[2-(methylsulfonyl)-1H-imidazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 209957-99-3 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminomethyl)phenyl]-3-ethyl-N-[2-fluoro-4-[2-(methylsulfonyl)-1H-imidazol-1-yl]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 209957-98-2
CMF C23 H23 F N6 O3 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 209958-28-1 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminomethyl)phenyl]-N-[4-[5-[(methoxyamino)carbonyl]-1H-imidazol-1-yl]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 209958-29-2 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminomethyl)phenyl]-N-[4-[5-[(methoxyamino)carbonyl]-1H-imidazol-1-yl]phenyl]-3-(trifluoromethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 209958-28-1
CMF C23 H20 F3 N7 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2

IT **209958-75-8P 209959-49-9P 209960-28-1P 209960-40-7P 209960-72-5P 209960-73-6P 209960-74-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of nitrogen-containing heteroaroms. as factor Xa inhibitors)
RN 209958-75-8 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-(3-cyanophenyl)-N-[4-(1H-imidazol-1-yl)phenyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 209959-49-9 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-(3-cyanophenyl)-3-methyl-N-[4-(2-methyl-1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 209960-28-1 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-(3-cyanophenyl)-N-[3-fluoro-4-(2-methyl-1H-imidazol-1-yl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 209960-40-7 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-(3-cyanophenyl)-3-ethyl-N-[2-fluoro-4-[2-(methylsulfonyl)-1H-imidazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 209960-72-5 CAPLUS
CN 1H-Imidazole-5-carboxylic acid, 1-[4-[[[1-(3-cyanophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]carbonyl]amino]phenyl]-, butyl ester (9CI) (CA INDEX NAME)



RN 209960-73-6 CAPLUS
CN 1H-Imidazole-5-carboxylic acid, 1-[4-[[[1-(3-cyanophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 209960-74-7 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-(3-cyanophenyl)-N-[4-[5-[(methoxyamino)carbonyl]-1H-imidazol-1-yl]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	59.73	232.68

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-8.76	-8.76

STN INTERNATIONAL LOGOFF AT 12:33:11 ON 10 AUG 2005